CIK 0001799788 · Non-accelerated filer<br>Smaller reporting company
Greenwich LifeSciences, Inc.
Sign in to watch- Ticker
- GLSI
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 205473709
- Phone
- 203-434-3290
- Business address
- 3992 BLUEBONNET DR, BUILDING 14, STAFFORD, TX, 77477
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-01-06 | Patel Snehal CEO and CFO | Purchase | +1,100 | $13.31 | $15K | 5,548,202 |
| 2025-01-03 | Patel Snehal CEO and CFO | Purchase | +3,400 | $12.95 | $44K | 5,547,102 |
| 2025-01-02 | Patel Snehal CEO and CFO | Purchase | +2,000 | $11.97 | $24K | 5,543,702 |
| 2024-12-31 | Patel Snehal CEO and CFO | Purchase | +2,400 | $11.36 | $27K | 5,541,702 |
| 2024-12-30 | Patel Snehal CEO and CFO | Purchase | +3,200 | $11.12 | $36K | 5,539,302 |
| 2024-12-24 | Patel Snehal CEO and CFO | Grant or award · Stock Options | +1,148,723 | 2,222,454 | ||
| 2024-12-24 | Patel Snehal CEO and CFO | Grant or award · Stock Options | +25,008 | 2,247,462 | ||
| 2024-12-24 | McWilliams David Director | Grant or award · Stock Options | +61,984 | 123,968 | ||
| 2024-12-24 | Thompson Jaye VP Clinical Reg Affairs | Grant or award · Stock Options | +149,818 | 299,636 | ||
| 2024-12-24 | Hallock Kenneth Director | Grant or award · Stock Options | +41,349 | 82,698 | ||
| 2024-12-24 | Daugherty Frank Joseph Chief Medical Officer | Grant or award · Stock Options | +104,890 | 209,780 | ||
| 2024-12-24 | Rothe Eric Director | Grant or award · Stock Options | +41,349 | 82,698 | ||
| 2024-11-21 | Thompson Jaye VP Clinical Reg Affairs | Purchase | +1,000 | $12.91 | $13K | 264,148 |
| 2024-09-26 | Patel Snehal CEO and CFO | Purchase | +1,500 | $14.63 | $22K | 5,536,102 |
| 2024-08-12 | Thompson Jaye VP Clinical Reg Affairs | Purchase | +800 | $13.85 | $11K | 263,148 |
| 2024-08-06 | Patel Snehal CEO and CFO | Purchase | +2,000 | $13.81 | $28K | 5,534,602 |
| 2024-08-05 | Patel Snehal CEO and CFO | Purchase | +5,500 | $13.18 | $72K | 5,532,602 |
| 2024-08-02 | Thompson Jaye VP Clinical Reg Affairs | Purchase | +1,000 | $15.15 | $15K | 262,348 |
| 2024-07-23 | Patel Snehal CEO and CFO | Purchase | +1,500 | $15.89 | $24K | 5,527,102 |
| 2024-07-18 | Thompson Jaye VP Clinical Reg Affairs | Purchase | +1,000 | $16.00 | $16K | 261,348 |
Page 2 of 10 · 190 trades